Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor
2013-005596-40Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in hemangiopericytoma (HPC) and soft tissue sarcoma (STS), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall tumor Response Rate (Choi criteria). Started Jan 2014; status: completed.
02
Drugs
axitinib
03
Conditions
hemangiopericytoma (HPC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2013-005596-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005596-40.